Chevy Chase Trust Holdings Inc. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 843,657 shares of the company’s stock after selling 1,452 shares during the period. Chevy Chase Trust Holdings Inc. owned approximately 0.08% of Eli Lilly and worth $69,433,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Joel Isaacson & Co. LLC grew its stake in shares of Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after acquiring an additional 50 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Eli Lilly and by 93.6% during the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares during the last quarter. Stephens Inc. AR grew its stake in shares of Eli Lilly and by 4.5% during the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after acquiring an additional 1,901 shares during the last quarter. BlackRock Inc. grew its stake in shares of Eli Lilly and by 2,628.5% during the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares during the last quarter. Finally, Blair William & Co. IL grew its stake in shares of Eli Lilly and by 13.1% during the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock worth $21,974,000 after acquiring an additional 30,299 shares during the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 590,000 shares of company stock valued at $48,551,300 over the last three months. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company (LLY) traded up 0.69% during mid-day trading on Monday, hitting $84.49. The stock had a trading volume of 1,253,910 shares. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The firm has a market cap of $89.14 billion, a P/E ratio of 36.56 and a beta of 0.34. The stock has a 50-day moving average price of $80.84 and a 200 day moving average price of $82.02.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.86 EPS. Equities analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/25/eli-lilly-and-company-lly-shares-sold-by-chevy-chase-trust-holdings-inc.html.

A number of equities research analysts recently commented on LLY shares. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet downgraded Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. BMO Capital Markets reaffirmed an “underperform” rating and set a $73.00 target price on shares of Eli Lilly and in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a report on Wednesday, July 26th. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Tuesday, May 30th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $88.27.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.